Medline’s IPO priced at $29 a share and is indicated to open about 16% higher at $33.50 after the medical-supplies maker raised $6.26 billion from an upsized sale of 216 million shares, giving it a pro forma market value near $39 billion. The listing—backed by private-equity owners Blackstone, Carlyle and Hellman & Friedman, who paid roughly $34 billion for a majority stake in 2021—included roughly $2.35 billion of cornerstone commitments and a synthetic secondary of more than 37 million shares to provide liquidity to pre-IPO holders. As the largest deal globally this year and the biggest U.S. IPO since Rivian in 2021, the transaction bolsters a muted IPO market (first-time U.S. raises this year exceed $46 billion excluding SPACs) and signals renewed capacity for large-scale listings ahead of potential blockbuster offerings such as SpaceX.
Medline Inc. priced its IPO at $29 per share and is indicated to open about 16% higher at $33.50 after raising $6.26 billion from an upsized sale of 216 million shares, giving a pro forma market value near $39 billion. The offering priced near the top of the marketed range, signaling strong investor demand for a healthcare-supply business that manufactures and distributes gloves, gowns and exam tables. The deal is the largest global IPO this year and the biggest U.S. listing since Rivian in 2021, surpassing CATL's $5.26 billion Hong Kong offering. Blackstone, Carlyle and Hellman & Friedman—who completed a roughly $34 billion majority-stake buyout in 2021—remain significant holders, while the IPO included about $2.35 billion of cornerstone commitments from institutional investors. Medline earmarked proceeds from the sale of more than 37 million shares for a synthetic secondary that lets pre-IPO shareholders realize gains without an outright direct sale, which will affect immediate sell-side supply dynamics. The mix of primary and secondary components reduces dilution to existing holders but creates a path for private-equity liquidity that investors should model when forecasting free float and post-listing pressure. The transaction contributes to a recovering but still-muted U.S. IPO market—first-time U.S. raises this year total about $46 billion excluding SPACs, below the pre-Covid annual average near $50 billion—and it may encourage other large listings into 2026. An indicated 16% open pop reflects near-term appetite, but the article provides no operating metrics or debt figures, so longer-term valuation hinges on prospectus disclosures and subsequent earnings. Investors should monitor the opening trade, lock-up schedules, and Medline's reported leverage and margin profile to determine whether the market premium is durable or driven primarily by scarcity and PE-backed demand.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
